Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation

Laurel A. Monticelli; Michael D. Buck; Anne Laure Flamar; Steven A. Saenz; Elia D.Tait Wojno; Naomi A. Yudanin; Lisa C. Osborne; Matthew R. Hepworth; Sara V. Tran; Hans Reimer Rodewald; Hardik Shah; Justin R. Cross; Joshua M. Diamond; Edward Cantu; Jason D. Christie; Erika L. Pearce; David Artis

doi:10.1038/ni.3421

Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation

Laurel A. Monticelli
, Michael D. Buck
, Anne Laure Flamar
, Steven A. Saenz
, Elia D.Tait Wojno
, Naomi A. Yudanin
, Lisa C. Osborne
, Matthew R. Hepworth
, Sara V. Tran
, Hans Reimer Rodewald
, Hardik Shah
, Justin R. Cross
, Joshua M. Diamond
, Edward Cantu
, Jason D. Christie
, Erika L. Pearce
, David Artis

Surgery

Research output: Contribution to journal › Article › peer-review

259 Scopus citations

Abstract

Group 2 innate lymphoid cells (ILC2s) regulate tissue inflammation and repair after activation by cell-extrinsic factors such as host-derived cytokines. However, the cell-intrinsic metabolic pathways that control ILC2 function are undefined. Here we demonstrate that expression of the enzyme arginase-1 (Arg1) during acute or chronic lung inflammation is a conserved trait of mouse and human ILC2s. Deletion of mouse ILC-intrinsic Arg1 abrogated type 2 lung inflammation by restraining ILC2 proliferation and dampening cytokine production. Mechanistically, inhibition of Arg1 enzymatic activity disrupted multiple components of ILC2 metabolic programming by altering arginine catabolism, impairing polyamine biosynthesis and reducing aerobic glycolysis. These data identify Arg1 as a key regulator of ILC2 bioenergetics that controls proliferative capacity and proinflammatory functions promoting type 2 inflammation.

Original language	English
Pages (from-to)	656-665
Number of pages	10
Journal	Nature Immunology
Volume	17
Issue number	6
DOIs	https://doi.org/10.1038/ni.3421
State	Published - May 19 2016

Bibliographical note

Publisher Copyright:
© 2016 Nature America, Inc.

Funding

We thank members of the D. Artis and G.F. Sonnenberg laboratories for critical reading of this manuscript. We thank R.M. Locksley (University of California, San Francisco, San Francisco, California, USA) for generously providing the Arg1YFP mice and B. Vallance (University of British Columbia, Vancouver, British Columbia, Canada) for providing Citrobacter rodentium. This work was supported by the National Institutes of Health (NIH) (grants AI061570, AI087990, AI074878, AI083480, AI095466, AI095608, AI102942 and AI097333 to D.A.; T32-AI007532 to L.A.M.; CA181125 and AI091965 to E.L.P.; HL087115, HL081619, HL096845, HL115354 and HL114626 to J.D.C.; HL116656 to E.C.; and HL090021 and K23-HL121406 to J.M.D.), the Burroughs Wellcome Fund (D.A. and E.L.P.), the Crohn's & Colitis Foundation of America (D.A. and M.R.H.), the Edmond J. Safra Foundation/Cancer Research Institute (L.C.O.), the National Science Foundation (grant DGE-1143954 to M.D.B.), the Robert Wood Johnson Foundation (grant AMFDP 70640 to E.C.), the Thoracic Surgery Foundation (E.C.) and the German Research Foundation (DFG SFB 873project 11 to H.-R.R.). We thank the Mucosal Immunology Studies Team (MIST) of the NIH NIAID for shared expertise and resources.

Funders	Funder number
D. Artis
Edmond J. Safra Foundation/Cancer Research Institute
National Science Foundation Arctic Social Science Program	DGE-1143954
National Institutes of Health (NIH)	AI061570, AI083480, AI102942, AI087990, HL096845, CA181125, AI095466, T32-AI007532, K23-HL121406, AI091965, AI074878, HL087115, HL116656, AI097333, HL115354, HL081619, HL090021, HL114626
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...	U01AI095608
Burroughs Wellcome Fund
Robert Wood Johnson Foundation	AMFDP 70640
Crohn's and Colitis Foundation of America
Thoracic Surgery Foundation
Deutsche Forschungsgemeinschaft	SFB 873project 11
Univ. of Northern British Columbia

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1038/ni.3421

Cite this

Monticelli, L. A., Buck, M. D., Flamar, A. L., Saenz, S. A., Wojno, E. D. T., Yudanin, N. A., Osborne, L. C., Hepworth, M. R., Tran, S. V., Rodewald, H. R., Shah, H., Cross, J. R., Diamond, J. M., Cantu, E., Christie, J. D., Pearce, E. L., & Artis, D. (2016). Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nature Immunology, 17(6), 656-665. https://doi.org/10.1038/ni.3421

@article{d2916206d29e49acbcb4a839100c16b4,

title = "Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation",

abstract = "Group 2 innate lymphoid cells (ILC2s) regulate tissue inflammation and repair after activation by cell-extrinsic factors such as host-derived cytokines. However, the cell-intrinsic metabolic pathways that control ILC2 function are undefined. Here we demonstrate that expression of the enzyme arginase-1 (Arg1) during acute or chronic lung inflammation is a conserved trait of mouse and human ILC2s. Deletion of mouse ILC-intrinsic Arg1 abrogated type 2 lung inflammation by restraining ILC2 proliferation and dampening cytokine production. Mechanistically, inhibition of Arg1 enzymatic activity disrupted multiple components of ILC2 metabolic programming by altering arginine catabolism, impairing polyamine biosynthesis and reducing aerobic glycolysis. These data identify Arg1 as a key regulator of ILC2 bioenergetics that controls proliferative capacity and proinflammatory functions promoting type 2 inflammation.",

author = "Monticelli, \{Laurel A.\} and Buck, \{Michael D.\} and Flamar, \{Anne Laure\} and Saenz, \{Steven A.\} and Wojno, \{Elia D.Tait\} and Yudanin, \{Naomi A.\} and Osborne, \{Lisa C.\} and Hepworth, \{Matthew R.\} and Tran, \{Sara V.\} and Rodewald, \{Hans Reimer\} and Hardik Shah and Cross, \{Justin R.\} and Diamond, \{Joshua M.\} and Edward Cantu and Christie, \{Jason D.\} and Pearce, \{Erika L.\} and David Artis",

note = "Publisher Copyright: {\textcopyright} 2016 Nature America, Inc.",

year = "2016",

month = may,

day = "19",

doi = "10.1038/ni.3421",

language = "English",

volume = "17",

pages = "656--665",

number = "6",

}

Monticelli, LA, Buck, MD, Flamar, AL, Saenz, SA, Wojno, EDT, Yudanin, NA, Osborne, LC, Hepworth, MR, Tran, SV, Rodewald, HR, Shah, H, Cross, JR, Diamond, JM, Cantu, E, Christie, JD, Pearce, EL & Artis, D 2016, 'Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation', Nature Immunology, vol. 17, no. 6, pp. 656-665. https://doi.org/10.1038/ni.3421

TY - JOUR

T1 - Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation

AU - Monticelli, Laurel A.

AU - Buck, Michael D.

AU - Flamar, Anne Laure

AU - Saenz, Steven A.

AU - Wojno, Elia D.Tait

AU - Yudanin, Naomi A.

AU - Osborne, Lisa C.

AU - Hepworth, Matthew R.

AU - Tran, Sara V.

AU - Rodewald, Hans Reimer

AU - Shah, Hardik

AU - Cross, Justin R.

AU - Diamond, Joshua M.

AU - Cantu, Edward

AU - Christie, Jason D.

AU - Pearce, Erika L.

AU - Artis, David

PY - 2016/5/19

Y1 - 2016/5/19

N2 - Group 2 innate lymphoid cells (ILC2s) regulate tissue inflammation and repair after activation by cell-extrinsic factors such as host-derived cytokines. However, the cell-intrinsic metabolic pathways that control ILC2 function are undefined. Here we demonstrate that expression of the enzyme arginase-1 (Arg1) during acute or chronic lung inflammation is a conserved trait of mouse and human ILC2s. Deletion of mouse ILC-intrinsic Arg1 abrogated type 2 lung inflammation by restraining ILC2 proliferation and dampening cytokine production. Mechanistically, inhibition of Arg1 enzymatic activity disrupted multiple components of ILC2 metabolic programming by altering arginine catabolism, impairing polyamine biosynthesis and reducing aerobic glycolysis. These data identify Arg1 as a key regulator of ILC2 bioenergetics that controls proliferative capacity and proinflammatory functions promoting type 2 inflammation.

AB - Group 2 innate lymphoid cells (ILC2s) regulate tissue inflammation and repair after activation by cell-extrinsic factors such as host-derived cytokines. However, the cell-intrinsic metabolic pathways that control ILC2 function are undefined. Here we demonstrate that expression of the enzyme arginase-1 (Arg1) during acute or chronic lung inflammation is a conserved trait of mouse and human ILC2s. Deletion of mouse ILC-intrinsic Arg1 abrogated type 2 lung inflammation by restraining ILC2 proliferation and dampening cytokine production. Mechanistically, inhibition of Arg1 enzymatic activity disrupted multiple components of ILC2 metabolic programming by altering arginine catabolism, impairing polyamine biosynthesis and reducing aerobic glycolysis. These data identify Arg1 as a key regulator of ILC2 bioenergetics that controls proliferative capacity and proinflammatory functions promoting type 2 inflammation.

UR - https://www.scopus.com/pages/publications/84962062339

UR - https://www.scopus.com/pages/publications/84962062339#tab=citedBy

U2 - 10.1038/ni.3421

DO - 10.1038/ni.3421

M3 - Article

C2 - 27043409

AN - SCOPUS:84962062339

SN - 1529-2908

VL - 17

SP - 656

EP - 665

JO - Nature Immunology

JF - Nature Immunology

IS - 6

ER -

Arginase 1 is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this